Ortho-Clinical Diagnostics™ VITROS™ Immunodiagnostic Products B·R·A·H·M·S PCT Reagent

Description

• Test delivers: High sensitivity and specificity for bacterial infection enables therapeutic decision making Results that are ready to be delivered to a clinicians with 96.5% First Pass Yield (without user intervention) Analytical performance: LOD at 0.007 ng/mL, LOQ (20% CV, observed) at 0.013 ng/mL Fast turnaround time: 24 minutes to first result Reliable solution: Not impacted by biotin interference Indicated as an aid to be used in conjunction with clinical evaluation for: Risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock Assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, using a change in PCT level over time Decision making on antibiotic therapy for patients with suspected or confirmed lower respiratory tract infections (LRTI) defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) – in an inpatient setting or an emergency department Decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis Indicated for use with the VITROS™ ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS™ 5600/XT 7600 Integrated Systems.